TY - JOUR
T1 - Antiarrhythmic drug therapy for ventricular arrhythmias
T2 - Current perspectives
AU - Link, Mark S.
AU - Homoud, Munther
AU - Foote, Caroline B.
AU - Wang, Paul J.
AU - Estes, N. A.Mark
PY - 1996
Y1 - 1996
N2 - Pharmacologic therapy for ventricular arrhythmias has undergone a remarkable change recently. Recognition of the importance of underlying structural heart disease on prognostic implications of ventricular arrhythmias has resulted in the refinement of the clinical classification of these arrhythmias. With refinement of techniques of risk stratification, it is now possible to identify patients with ventricular arrhythmias at high risk for sudden death. Retrospective analyses of prior antiarrhythmic drug trials and new data from prospective randomized trials are now available and can more directly define the risks and benefits of antiarrhythmic therapy. Prevention of sudden death, reduction in total mortality, or improvement in symptoms remain the only benefits of antiarrhythmic drugs. With inclusion of total mortality as the major endpoint for assessment of pharmacologic interventions in high-risk patients, the potential for excess mortality due to antiarrhythmic agents is now recognized. The pharmacologic diversity of newly released antiarrhythmic agents and others under development has resulted in a re-evaluation of the traditional classification of these drugs. Multiple ongoing clinical trials will define the risks and benefits of antiarrhythmic therapy and other nonpharmacologic interventions in patients with ventricular arrhythmias.
AB - Pharmacologic therapy for ventricular arrhythmias has undergone a remarkable change recently. Recognition of the importance of underlying structural heart disease on prognostic implications of ventricular arrhythmias has resulted in the refinement of the clinical classification of these arrhythmias. With refinement of techniques of risk stratification, it is now possible to identify patients with ventricular arrhythmias at high risk for sudden death. Retrospective analyses of prior antiarrhythmic drug trials and new data from prospective randomized trials are now available and can more directly define the risks and benefits of antiarrhythmic therapy. Prevention of sudden death, reduction in total mortality, or improvement in symptoms remain the only benefits of antiarrhythmic drugs. With inclusion of total mortality as the major endpoint for assessment of pharmacologic interventions in high-risk patients, the potential for excess mortality due to antiarrhythmic agents is now recognized. The pharmacologic diversity of newly released antiarrhythmic agents and others under development has resulted in a re-evaluation of the traditional classification of these drugs. Multiple ongoing clinical trials will define the risks and benefits of antiarrhythmic therapy and other nonpharmacologic interventions in patients with ventricular arrhythmias.
KW - antiarrhythmic agents
KW - sudden cardiac death
KW - ventricular premature beats
KW - ventricular tachycardia
UR - http://www.scopus.com/inward/record.url?scp=0029977527&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029977527&partnerID=8YFLogxK
U2 - 10.1111/j.1540-8167.1996.tb00573.x
DO - 10.1111/j.1540-8167.1996.tb00573.x
M3 - Review article
C2 - 8807411
AN - SCOPUS:0029977527
SN - 1045-3873
VL - 7
SP - 653
EP - 670
JO - Journal of Cardiovascular Electrophysiology
JF - Journal of Cardiovascular Electrophysiology
IS - 7
ER -